Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Millions of people around the world suffer from acid reflux or chronic heartburn. But many don’t realize this condition can develop into a precancerous disease called Barrett’s esophagus.4
Barrett’s esophagus is the primary risk factor for esophageal adenocarcinoma (EAC), a form of esophogeal cancer.5 Patients with Barrett's esophagus are up to 40 times more likely to develop EAC than those who do not have it.6 If detected early, it's possible to treat Barrett’s esophagus and reduce your risk for esophageal cancer.1,2
Don't wait for your condition to worsen. Visit a gastroenterologist for a diagnosis and personalized treatment plan.
Information and resources on this site should not be used as a substitute for medical advice from your doctor. Always discuss diagnosis and treatment information including risks with your doctor. Keep in mind that all treatment and outcome results are specific to the individual patient. Results may vary.
Shaheen NJ, Sharma P, et al. Radiofrequency Ablation in Barrett’s Esophagus with Dysplasia. New England Journal of Medicine 2009 May; 360(22):2277-2288.
Phoa KY, van Vilsteren FG, Pouw RE, Bergman J et al. Radiofrequency Ablation vs Endoscopic Surveillance for Patients with Barrett Esophagus and Low-Grade Dysplasia A Randomized Clinical Trial. JAMA. 2014; 311(12):1-10.
Wolf WA, Lightdale CJ, Li N, et al. Incidence of Esophageal Adenocarcinoma (EAC) in Patients with Barrett’s esophagus (BE) Undergoing Radiofrequency Ablation. Gastroenterology. 2015 Aug 28.(15)1245-7.
Vaezi M, Zehrai A, Yuksel E, Testing for refractory gastroesophageal reflux disease, ASGE Leading Edge, 2012 Vol 2, No 2, 1-13, American Society Gastroenterology Endoscopy, Page 1.
Spechler S. et al. Barrett’s Esophagus. N Engl J Med. 2014; 371:836-45.
Wani S, Falk G, Hall M, Gaddam S, Wang A, Gupta N, et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2011;9(3):220-7.